CME GROUP INC.

CME · Other · FY2025 filings · Narrow moat ·

On the watchlist

Narrow moat
Share / Embed this score
Embed this score

The five investor questions

Revenue & EPS trend86

2007–2025: revenue 1756100000.00 to 6520600000.00, increasing; diluted EPS 2.99 to 11.16, increasing.

Pricing power

Not enough years of gross-margin data to score pricing power.

Returns on capital24

Median ROIC 9.0%, above the 12% hurdle in 20% of years.

Balance-sheet safety100

Net cash position — no leverage risk.

Capital discipline77

Owner earnings +11.2%/yr, share count n/a.

The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.

Price vs. owner-earnings value range

Above estimateBelow estimate
No price data
Owner earnings (normalized)
$3.3B
Value range / share
Conservative high estimate / share
Recent price
$245.11
Price vs. high estimate
No price data

Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 4% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

20 years of fundamentals

The business, in plain English

Across the filed record, revenue grew from $1.8B (FY2007) to $6.5B (FY2025) — about 7.6% a year compounded over 18 years.

It earned 13.3% on invested capital in FY2025, with a median of 8.0% across 19 filed years. The Returns on Capital filter above scores it 24/100.

The balance sheet carried $0 of total debt in FY2025 against $4.1B of owner earnings — roughly 0.0 years of owner earnings to retire it all. Balance-Sheet Safety scores it 100/100.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2006–FY2025 · 20 fiscal years, normalized from CME’s SEC filings

RevenueSales, as filed$6.5B FY2025
$0$2.5B$5B2006201320202025
Gross marginRevenue kept after cost of goods

Not disclosed in CME’s filings for these years — we don’t estimate it.

Return on invested capitalOperating profit on the capital employed13.3% FY2025
0%5%10%2006201320202025
Owner earningsCash an owner could take out$4.1B FY2025
$0$2B$4B2006201320202025

Gaps in a line mean that item isn’t in CME’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

9 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale71.8 / 100
0406080100WideNarrowShallowNo moatJul 20, 2026Jul 21, 2026

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

  1. Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Track record

How CME GROUP INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

As-of scores 20112025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

As-of Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored CME on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatAs-of Moat Score1002005001,000Indexed price · log scale (2012 = 100)201120142017202020232026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, CME did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Other context

#12 of 45 scored Other companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #10WT WisdomTree, Inc.78.3 out of 100, Narrow moatNarrow moat
  2. #11SEIC SEI INVESTMENTS COMPANY78.2 out of 100, Narrow moatNarrow moat
  3. #13CBOE Cboe Global Markets, Inc.70.6 out of 100, Narrow moatNarrow moat
  4. #14GCMG GCM Grosvenor Inc.70.6 out of 100, Narrow moatNarrow moat

Compare CME with its nearest peersAll Other companies on the Index →

Common questions about CME

Does CME GROUP INC. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores CME GROUP INC. (CME) 71.8 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 86, pricing power not measurable from the filings, returns on capital 24, balance-sheet safety 100, capital discipline 77.
How has CME's Moat Score changed over time?
The record logs 9 readings since Jul 17, 2026; the latest reads 71.8 out of 100 (narrow moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.
CME GROUP INC. (CME) Moat Score — The Moat Index · Buy Like Buffett